Bioconjugate polysaccharide vaccines
Founded in 2016 by Mario Feldman and Christian Harding, Omniose develops bioconjugate polysaccharide vaccines targeting bacterial pathogens using a proprietary glycoconjugation platform.
لا توجد بيانات
لا توجد عناصر FAQ.